BlackRock
NVCT icon

BlackRock’s Nuvectis Pharma NVCT Stock Holding History

BlackRock’s Portfolio NVCT Stock Details NVCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$18.4M Buy
1,001,285
+236,844
+31% +$2.65M ﹤0.01% 3317
2026
Q1 		$5.91M Sell
764,441
-18,364
-2% -$157K ﹤0.01% 3758
2025
Q4 		$5.91M Buy
782,805
+97,468
+14% +$635K ﹤0.01% 3764
2025
Q3 		$4.13M Buy
685,337
+42,355
+7% +$291K ﹤0.01% 3851
2025
Q2 		$4.8M Buy
642,982
+574,498
+839% +$5.21M ﹤0.01% 3792
2025
Q1 		$669K Buy
68,484
+6,142
+10% +$44.2K ﹤0.01% 4314
2024
Q4 		$337K Buy
62,342
+12,788
+26% +$80.1K ﹤0.01% 4517
2024
Q3 		$312K Sell
49,554
-33,858
-41% -$223K ﹤0.01% 4430
2024
Q2 		$528K Sell
83,412
-289,309
-78% -$1.97M ﹤0.01% 4332
2024
Q1 		$3.06M Sell
372,721
-15,170
-4% -$129K ﹤0.01% 3856
2023
Q4 		$3.24M Buy
387,891
+28,444
+8% +$254K ﹤0.01% 3862
2023
Q3 		$4.63M Buy
359,447
+44,956
+14% +$651K ﹤0.01% 3686
2023
Q2 		$5.02M Buy
314,491
+300,935
+2,220% +$4.8M ﹤0.01% 3728
2023
Q1 		$178K Buy
13,556
+3,395
+33% +$34.4K ﹤0.01% 4811
2022
Q4 		$76.2K Sell
10,161
-3,842
-27% -$27.5K ﹤0.01% 5122
2022
Q3 		$100K Buy
14,003
+6,805
+95% +$63.4K ﹤0.01% 5173
2022
Q2 		$80K Sell
7,198
-674
-9% -$8.33K ﹤0.01% 5297
2022
Q1 		$59K Buy
+7,872
New +$54.8K ﹤0.01% 5389

Other funds holding NVCT

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
IAM
Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
OCM
Occam Crest Management Darien, Connecticut $193M AUM 233.09% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
BWP
Baldwin Wealth Partners Marion, Massachusetts $1.53B AUM 28.5% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

BlackRock's NVCT Position: Q2 2026 in Review

BlackRock increased its Nuvectis Pharma (NVCT) stake by 31% in Q2 2026, buying an estimated $2.65M and bringing the position to 1,001,285 shares worth $18.4M. The position accounts for ﹤0.01% of the portfolio, ranked #3317.

BlackRock first reported a position in NVCT in Q1 2022 and has held it in 18 quarters since. 83 funds tracked by Wall St. Rank hold NVCT as of Q2 2026.

  • BlackRock held 1,001,285 shares of Nuvectis Pharma worth $18.4M as of Q2 2026.
  • BlackRock bought 236,844 Nuvectis Pharma shares in Q2 2026, an estimated $2.65M.
  • Nuvectis Pharma made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #3317 holding.
  • BlackRock first reported a position in Nuvectis Pharma in Q1 2022 and has held it in 18 quarters since.
  • 83 funds tracked by Wall St. Rank held Nuvectis Pharma as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.